A concerted effort to collect and bank tissues and biologic fluids from the upper respiratory tract has been an ongoing effort since 1990 under the direction of the Pathology Core leader. Initially, specimen collection primarily targeted overtly malignant carcinomas. Over time, the focus of specimen collection has shifted to tissues and biologic fluids representing much earlier stages along the tumor progression pathway and specimens from control patients without head and neck cancer. The availability of these tissues and cells has contributed to the work of many of the investigators participating in the SPORE, resulting over the years in significant discoveries with high translational impact and numerous peer-reviewed publications. The Pathology Core will continue to: 1) collect, store, process and distribute tissues and biologic fluids for translational research without compromise of patient care;2) provide well-characterized tumors with respect to site of origin, Worid Health Organization histologic subtype, differentiation, and fraction of neoplastic and stromal tissues;3) provide normal control tissue in addition to neoplasms;4) process and store tissues to address the requirements of all SPORE investigators;5) include neoplasms with a wide range of biologic potential (e.g. normal, dysplasia, carcinoma sequence);6) perpetuate tumor growth and expand tumor availability by xenografting tumors into immunodeficient mice;7) collect blood and exfoliated cells (e.g. oral rinses/oral brushes) from pertinent patients for the SPORE projects;8) provide the specimens in a timely fashion;and 9) provide well-defined mechanisms for prioritization of the distribution of requested resources to investigators within and external to the Johns Hopkins SPORE.
The availability of high quality and well characterized human specimens is central and vital to translational research. The provisions of these specimens is imperative to the success of the SPORE projects.
|Guo, Theresa; Sakai, Akihiro; Afsari, Bahman et al. (2017) A Novel Functional Splice Variant of AKT3 Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers. Cancer Res 77:5248-5258|
|Kang, Hyunseok; Tan, Marietta; Bishop, Justin A et al. (2017) Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. Clin Cancer Res 23:283-288|
|Bishop, Justin A; Westra, William H (2017) MYB Translocation Status in Salivary Gland Epithelial-Myoepithelial Carcinoma: Evaluation of Classic, Variant, and Hybrid Forms. Am J Surg Pathol :|
|Zhang, Hongzheng; Kim, Sungjin; Chen, Zhengjia et al. (2017) Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head Neck 39:2433-2443|
|Bishop, Justin A; Rooper, Lisa M; Chiosea, Simion I et al. (2017) Clear Cell Carcinoma of Salivary Glands is Frequently p16 Positive: A Pitfall in the Interpretation of Oropharyngeal Biopsies. Am J Surg Pathol :|
|Anagnostou, Valsamo; Smith, Kellie N; Forde, Patrick M et al. (2017) Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov 7:264-276|
|Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188|
|Peri, Suraj; Izumchenko, Evgeny; Schubert, Adrian D et al. (2017) NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nat Commun 8:1772|
|Weidhaas, Joanne B; Harris, Jonathan; Schaue, Dörthe et al. (2017) The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 3:483-491|
|Guerrero-Preston, Rafael; White, James Robert; Godoy-Vitorino, Filipa et al. (2017) High-resolution microbiome profiling uncovers Fusobacterium nucleatum, Lactobacillus gasseri/johnsonii, and Lactobacillus vaginalis associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and Oncotarget 8:110931-110948|
Showing the most recent 10 out of 122 publications